Losing control of nutrient sensing in the germinal centre drives lymphomagenesis by Klein, U
This is a repository copy of Losing control of nutrient sensing in the germinal centre drives 
lymphomagenesis.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/164339/
Version: Accepted Version
Article:
Klein, U orcid.org/0000-0002-4789-967X (2019) Losing control of nutrient sensing in the 
germinal centre drives lymphomagenesis. Nature Metabolism, 1 (8). pp. 750-751. ISSN 
2522-5812 
https://doi.org/10.1038/s42255-019-0103-2
© 2019, Springer Nature. This is an author produced version of an article published in 
Nature Metabolism. Uploaded in accordance with the publisher's self-archiving policy.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Cancer metabolism 
 
Losing control of nutrient sensing in the germinal center drives lymphomagenesis 
 
Ulf Klein 
Division of Haematology & Immunology 
Leeds Institute of Medical Research at St. JamesÕs 
University of Leeds 
Leeds, LS9 7TF 
UK 
 
Corresponding author 
Ulf Klein 
U.P.Klein@leeds.ac.uk 
 
The gene encoding RagC GTPase (RRAGC), an activator of a nutrient-sensing 
pathway that drives cellular anabolism, is mutated in 15% of follicular lymphoma 
cases. A new study provides evidence that RRAGC mutations promote 
lymphomagenesis by distorting a nutrient-dependent control of paracrine signals 
from the microenvironment, resulting in enhanced B-cell activation.  
 
Follicular lymphoma (FL) is an indolent but largely incurable non-Hodgkin lymphoma 
originating from the clonal expansion of germinal center (GC) B-cells,1 a specialized 
subset of B-cells that during a T cell-dependent immune response modify their 
rearranged immunoglobulin variable region genes to generate highly specific, pathogen-
eliminating antibodies.2,3 The genetic hallmark of FL is the t(14;18) chromosomal 
translocation that constitutively activates the anti-apoptotic gene BCL2, along with 
recurrent mutations of histone modifier genes.1 Additional genetic mutations affecting 
various biological pathways have been identified by genomic analyses,1,4 including 
aberrations in components of the cellular nutrient-sensing pathway. Specifically, a 
sizable subset of FL cases show missense mutations in the nucleotide binding domain of 
the gene encoding the RagC GTPase (RRAGC).5,6 This enzyme forms a heterodimeric 
complex together with RagA GTPase, which activates mTORC1 when cellular nutrients 
are sufficient, leading to cell growth.7,8 Curiously, RagA, despite encompassing a part of 
the mTORC1-activating complex, is not targeted by mutations in FL.5,6 These 
observations raised two questions: 1) how do mutations in RRAGC promote FL 
pathogenesis; and 2) what is the basis for the selectivity of mutations in RRAGC, while 
sparing RagA? Through mimicking the FL-associated RRAGC mutations in the mouse 
germline and crossing those mice to an established FL animal model, Ortega-Molina et 
al. uncovered a role for RagC in normal GC B-cell development and FL pathogenesis.9  
 
Employing CRISPR/Cas9 genome engineering, Ortega-Molina et al. generated two 
independent Rragc knockin-mouse models that mimic the most frequent human variants 
of activating RRAGC mutations.9 In order to assess the presumed aberrant activity of 
mutated RagC in vitro, amino acids and growth factors that would elicit mTORC1 
activation were omitted from the culture medium. Under these conditions, B-cells of the 
mutant mouse lines showed a greater mTORC1 activity than wild-type mice upon T cell-
mediated activating signals that during an immune response stimulate the mTORC1 
pathway via the PI3K-AKT axis (Fig. 1A), suggesting a partial insensitivity to nutrient 
withdrawal (Fig. 1B). The same was observed on a Bcl2-transgenic background using 
VavP-Bcl2 transgenic mice,10 which also revealed accelerated FL development in vivo.9 
Transcriptional profiling analysis showed enrichment of the mTORC1 signature in RagC-
mutated FL cells, and a marked overlap in the differential expression of the 
corresponding genes in RRAGCÐmutated murine and human FL. These results suggest 
that RagC-mediated enhancement of mTORC1 activation promotes FL pathogenesis 
also in humans.  
 In order to gain insights into the pathogenic mechanism of mutated RagC in FL 
development, the authors determined the biological effects of the mutated gene in the 
normal cellular counterpart of FL. Upon immunizing RagC-mutated mice with a T cell-
dependent antigen, the authors observed a dramatic increase in the abundance of GC 
B-cells compared to wild-type controls.9 The difference was even more remarkable in a 
competitive reconstitution setting where RagC mutant and wild-type B-cells were 
assessed in their ability to generate GCs in the same mouse. Mechanistically, the 
authors provide evidence that this increase in RagC mutant cells is likely due to 
suppression of cell death and to a decreased requirement of the RagC-mutated GC B-
cells on microenvironmental signals provided by T-follicular helper (Tfh) cells, the CD4+ 
T-cells that control the GC reaction. The latter was evident from the observation that 
despite the massive enlargement of GCs in the RagC-mutated mice, the number of Tfh-
cells per GC was similar to that of control mice. Since Tfh-cells are required for GC 
maintenance, the decrease in the Tfh/GC B-cell ratio suggests that Rragc mutations 
promote lymphomagenesis by substituting PI3K-AKT-derived mTORC1-activating 
signals through the Rag GTPase-mediated nutrient-sensing pathway (Fig. 1B).  
 
Now, if aberrant Rag GTPase function promotes FL pathogenesis via mTORC1 
activation, why are no activating mutations observed in RagCÕs heterodimeric partner 
RagA? Ortega-Molina et al. provide evidence for what they call a Ôbiochemical 
asymmetryÕ of the Rag heterodimers in the activation of mTORC1. Unlike observed for 
mutated RagC that was sensitive to nutrient withdrawal, an activating mutation in RagA 
had no effect on the regulation of mTORC1 under the same condition.9 Moreover, the 
RagA mutation did not lead to GC enlargement, and constitutive activation of RagA in 
GC B-cells actually impaired the GC response by decreasing GC B-cell fitness, similar to 
what has previously been observed for mTORC1 hyperactivation.11 Specifically, strong 
mTORC1 activation negatively impacted the generation of high-affinity antibodies 
against the immunizing antigen, which in a competitive setting led to the disappearance 
of mTORC1-hyperactive versus wild-type GC B-cells over time.11 Conversely, mutations 
in RagC were found to increase the production of high-affinity antibodies.8 Based on 
these findings, the authors propose a model in which the mutations in RagC, as opposed 
to those in RagA, lead to a modest activation of the mTORC1 pathway that increases 
GC B-cell fitness (Fig. 1B).  
 
But how would an increased fitness of RagC-mutated GC B-cells contribute to the 
multistep process of FL development? Adding to the pro-survival signals provided by the 
BCL2 translocation, RagC-induced mTORC1 activation may further suppress the default 
apoptotic program of GC B-cells by enhancing activating Tfh cell-derived signals, which 
also funnel into the mTORC pathway. This pre-malignant GC B-cell has a competitive 
advantage over normal GC B-cells with similar antigen-affinities and keeps undergoing 
iterative cycles of selection and proliferation within the GC, during which it may acquire 
additional genetic aberrations, ultimately developing into a bone fide lymphoma. 
 
Then the pressing question is whether enhanced mTORC1 activity in FL with Rragc 
mutations and Bcl2-translocations can be exploited for lymphoma therapy. Experiments 
performed by Ortega-Molina et al. with the mTOR inhibitor rapamycin indicate that such 
mice, in contrast to mice with Bcl2-translocations only, showed a lower incidence and 
grade of lymphomas.9 The observed higher selective sensitivity to mTORC1 inhibition in 
this mouse model suggests that patients with mutations in the nutrient-signaling pathway 
may benefit from treatment with mTOR inhibitors.       
 
Finally, the authors propose that a different genetic aberration in FL may act in a similar 
manner as RRAGC mutations. Loss-of-function mutations or deletions of TNFRSF14 
that ablate the function of Herpes virus entry mediator (HVEM) are associated with an 
increased cellularity of Tfh-cells in the tumor microenvironment.12 A meta-analysis of 
genomic data from human FL samples revealed that TNFRSF14 mutations are largely 
mutually exclusive with RRAGC mutations.9 Intriguingly, a recent publication reports that 
HVEM deficiency was associated with increased B-cell competitiveness during the GC 
reaction,13 mirroring what Ortega-Molina et al. observed for RagC-mutated B-cells. 
Therefore, it seems that Tfh cell-derived signals may promote lymphoma growth either 
by cell-autonomous mutations that synergize with those signals, as observed for 
RRAGC mutations, or by abnormally high Tfh-cell numbers as in the case of TNFRSF14 
deficiency. The findings by Ortega-Molina et al. provide important new insights into the 
molecular mechanisms of FL pathogenesis. In future studies, the potential tumor 
metabolic vulnerability identified in the present work may be exploited for the 
development of precision medicine-based therapies. 
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Figure Legend 
Figure 1: Model for the effects of RagC mutations on GC B-cell development and 
lymphomagenesis. A) The nutrient signaling pathway imposes an Ôanabolic capacityÕ 
barrier over B-cell activation by T-cell help (and B-cell receptor signaling, not shown), 
ensuring that growth occurs only if nutrients are sufficient. GC B-cells are clonally 
selected for the expression of high-affinity antibodies (adequate B-cell competitiveness). 
B) RagC mutations weaken this barrier and cause enhanced B-cell activation, while 
retaining the ability to suppress activation when nutrient levels are low. These mutations 
lead to an increased B-cell competitiveness, which translates into enhanced B-cell 
growth and survival. Upon acquiring additional transforming events, the GC B-cell 
ultimately develops into a lymphoma. RagC-mutated cells are sensitive to Rapamycin-
mediated pharmacological inhibition of mTORC1. Adapted from Fig, 6 of ref. 9. 
 
